Clinical Trial ResultsEvorpacept combined with standard-of-care demonstrates a high complete response rate, indicating strong potential for treating B-cell Non-Hodgkin Lymphoma.
Drug Safety ProfileThe combination therapy involving evorpacept was generally well tolerated, with no dose-limiting toxicities, suggesting a favorable safety profile.
Financial OutlookAnalysts maintain a Buy rating on ALXO with a price target based on projected future revenues from evorpacept, highlighting confidence in the drug’s financial prospects.